Logo image of 1COV.DE

COVESTRO AG (1COV.DE) Stock Fundamental Analysis

FRA:1COV - Deutsche Boerse Ag - DE0006062144 - Common Stock - Currency: EUR

60.09  +0.11 (+0.18%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to 1COV. 1COV was compared to 65 industry peers in the Chemicals industry. 1COV may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, 1COV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year 1COV has reported negative net income.
In the past year 1COV had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: 1COV reported negative net income in multiple years.
Each year in the past 5 years 1COV had a positive operating cash flow.
1COV.DE Yearly Net Income VS EBIT VS OCF VS FCF1COV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

Looking at the Return On Assets, with a value of -2.78%, 1COV is doing worse than 67.69% of the companies in the same industry.
1COV's Return On Equity of -6.10% is on the low side compared to the rest of the industry. 1COV is outperformed by 64.62% of its industry peers.
Industry RankSector Rank
ROA -2.78%
ROE -6.1%
ROIC N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
1COV.DE Yearly ROA, ROE, ROIC1COV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

In the last couple of years the Operating Margin of 1COV has declined.
1COV's Gross Margin of 14.41% is on the low side compared to the rest of the industry. 1COV is outperformed by 76.92% of its industry peers.
In the last couple of years the Gross Margin of 1COV has declined.
1COV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.41%
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
1COV.DE Yearly Profit, Operating, Gross Margins1COV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

3

2. Health

2.1 Basic Checks

1COV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 1COV has about the same amount of shares outstanding.
1COV has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 1COV has an improved debt to assets ratio.
1COV.DE Yearly Shares Outstanding1COV.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
1COV.DE Yearly Total Debt VS Total Assets1COV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

1COV has an Altman-Z score of 2.21. This is not the best score and indicates that 1COV is in the grey zone with still only limited risk for bankruptcy at the moment.
1COV has a Altman-Z score (2.21) which is in line with its industry peers.
1COV has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
1COV has a Debt to Equity ratio of 0.31. This is in the better half of the industry: 1COV outperforms 64.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 2.21
ROIC/WACCN/A
WACC6.26%
1COV.DE Yearly LT Debt VS Equity VS FCF1COV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

A Current Ratio of 1.32 indicates that 1COV should not have too much problems paying its short term obligations.
With a Current ratio value of 1.32, 1COV is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
1COV has a Quick Ratio of 1.32. This is a bad value and indicates that 1COV is not financially healthy enough and could expect problems in meeting its short term obligations.
1COV has a worse Quick ratio (0.71) than 86.15% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.71
1COV.DE Yearly Current Assets VS Current Liabilites1COV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

4

3. Growth

3.1 Past

1COV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -90.83%.
Looking at the last year, 1COV shows a small growth in Revenue. The Revenue has grown by 0.01% in the last year.
Measured over the past years, 1COV shows a small growth in Revenue. The Revenue has been growing by 2.70% on average per year.
EPS 1Y (TTM)-90.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-347.37%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-0.94%

3.2 Future

Based on estimates for the next years, 1COV will show a very strong growth in Earnings Per Share. The EPS will grow by 40.14% on average per year.
1COV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.06% yearly.
EPS Next Y122.42%
EPS Next 2Y88.03%
EPS Next 3Y60.44%
EPS Next 5Y40.14%
Revenue Next Year2.12%
Revenue Next 2Y3.66%
Revenue Next 3Y3.32%
Revenue Next 5Y4.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
1COV.DE Yearly Revenue VS Estimates1COV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B
1COV.DE Yearly EPS VS Estimates1COV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 1COV. In the last year negative earnings were reported.
1COV is valuated quite expensively with a Price/Forward Earnings ratio of 27.56.
64.62% of the companies in the same industry are cheaper than 1COV, based on the Price/Forward Earnings ratio.
1COV's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.17.
Industry RankSector Rank
PE N/A
Fwd PE 27.56
1COV.DE Price Earnings VS Forward Price Earnings1COV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

1COV's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.19
1COV.DE Per share data1COV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as 1COV's earnings are expected to grow with 60.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y88.03%
EPS Next 3Y60.44%

More info and screens

0

5. Dividend

5.1 Amount

1COV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COVESTRO AG

FRA:1COV (6/3/2025, 5:29:46 PM)

60.09

+0.11 (+0.18%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)07-31 2025-07-31
Inst Owners47.64%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap11.36B
Analysts67.62
Price Target62.97 (4.79%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.01
Dividend Growth(5Y)-70.61%
DP-0.26%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-691.25%
Min EPS beat(2)-1222.75%
Max EPS beat(2)-159.74%
EPS beat(4)1
Avg EPS beat(4)-3758.66%
Min EPS beat(4)-13853.1%
Max EPS beat(4)201.01%
EPS beat(8)1
Avg EPS beat(8)-4303.1%
EPS beat(12)2
Avg EPS beat(12)-2871.29%
EPS beat(16)4
Avg EPS beat(16)-2153.19%
Revenue beat(2)0
Avg Revenue beat(2)-4.8%
Min Revenue beat(2)-5.09%
Max Revenue beat(2)-4.5%
Revenue beat(4)0
Avg Revenue beat(4)-4.72%
Min Revenue beat(4)-6.71%
Max Revenue beat(4)-2.59%
Revenue beat(8)0
Avg Revenue beat(8)-4.65%
Revenue beat(12)2
Avg Revenue beat(12)-2.45%
Revenue beat(16)5
Avg Revenue beat(16)-1.22%
PT rev (1m)0%
PT rev (3m)1.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-76.86%
Revenue NQ rev (1m)-4.67%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.85%
Revenue NY rev (3m)-2.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.56
P/S 0.8
P/FCF N/A
P/OCF 13.85
P/B 1.77
P/tB 2.17
EV/EBITDA 15.19
EPS(TTM)-2.08
EYN/A
EPS(NY)2.18
Fwd EY3.63%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)4.34
OCFY7.22%
SpS74.85
BVpS33.9
TBVpS27.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.78%
ROE -6.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.41%
FCFM N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)6.03%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
F-Score3
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA 2.09
Cap/Depr 84.99%
Cap/Sales 6.04%
Interest Coverage N/A
Cash Conversion 87.7%
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 0.71
Altman-Z 2.21
F-Score3
WACC6.26%
ROIC/WACCN/A
Cap/Depr(3y)75.52%
Cap/Depr(5y)82.02%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-347.37%
EPS Next Y122.42%
EPS Next 2Y88.03%
EPS Next 3Y60.44%
EPS Next 5Y40.14%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-0.94%
Revenue Next Year2.12%
Revenue Next 2Y3.66%
Revenue Next 3Y3.32%
Revenue Next 5Y4.06%
EBIT growth 1Y-134.13%
EBIT growth 3Y-79.32%
EBIT growth 5Y-52.83%
EBIT Next Year364.32%
EBIT Next 3Y92.23%
EBIT Next 5Y56.01%
FCF growth 1Y-94.44%
FCF growth 3Y-60.36%
FCF growth 5Y-28.37%
OCF growth 1Y3.27%
OCF growth 3Y-26.52%
OCF growth 5Y-8.84%